Fluenza virus, flavi- and paramyxoviruses (Elia et al., 2008; Galli et al., 2018; Li et al., 2008; Briolant et al., 2004; Smee et al., 2001; Leyssen et al., 2005). A study observed decreased replication of your MERS-CoV in rhesus macaques upon remedy with IFN-2b and RBV (Falzarano et al., 2013). RBV in combination with LPV/RTV was employed in SARS-CoV and MERS-CoV trials (Yao T. et al., 2020). Inside the case of SARS-CoV-2 infection, an in vitro study determined the EC50 of RBV as 109.50uM (Wang X. et al., 2020). A study integrated RBV in addition to LPV/RTV and IFN- within the HDAC8 Inhibitor manufacturer therapy of hospitalized COVID-19 patients (Hung et al., 2020). The triple therapy was found to be advantageous to decrease illness symptoms and virus shedding when compared with groups provided LPV-RTV alone. The dose of RBV regarded was 400mg bid in conjunction with 400mg/100mg of LPV/RTV + IFN- for 14days. A study assessed the effect of sofosbuvir/daclatasvir (antivirals) compared to RBV in treatment of COVID-19 patients. The mortality was higher (33 ) in COVID-19 individuals treated with RBV than that of sofosbuvir/daclatasvir (Eslami et al., 2020). A retrospective cohort study comparing RBV vs. supportive therapy stated that RBV didn’t enable in decreasing the mortality rate in COVID-19 patients (Tong et al., 2020). 15 clinical trials CXCR Antagonist Biological Activity happen to be registered for the use of RBV alone or in combination with other COVID-19 drugs (ClinicalTrials.gov, 2020h).United states of america stated that neither HCQ nor AZM separately or with each other could reduce the mortality of COVID-19 patients when compared with the handle group (Rosenberg et al., 2020). Furthermore, therapy of AZM and HCQ was connected with greater adjustments in QTc in COVID-19 patients (Mercuro et al., 2020). Handful of other studies also reported that AZM integrated in treating COVID-19 patients did not provide any helpful effect (Rodr uez-Molinero et al., 2020; Furtado et al., 2020; Cavalcanti et al., 2020). 122 clinical trials happen to be registered for the use of AZM alone or in combination with other drugs against COVID19 (ClinicalTrials.gov, 2020a).UmifenovirUmifenovir (UFV) is definitely an indolyl carboxylic acid extensively recognized as Arbidol (Blaising et al., 2014). It can be used as a therapy and prevention measure against influenza virus (Blaising et al., 2014). It has direct antiviral and host-targeting action. UFV can interact with virus protein or lipid elements and may possibly hinder unique stages from the viral life cycle (Blaising et al., 2014). In vitro analysis on the antiviral activity of arbidol against various human respiratory viruses, namely influenza-A virus, respiratory syncytial virus, rhinovirus type-14, coxsackievirus-B3 and adenovirus type-7 is demonstrated (Shi et al., 2007). Inhibition of SARS-CoV replication on UFV treatment was demonstrated in vitro. UFV is also identified to inhibit many isolates of zika virus in many cell lines (Fink et al., 2018). The inhibitory action in the drug against SARS-CoV-2 in Vero E6 cells (MOI of 0.05) has been demonstrated. The EC50 and CC50 were 4.11 and 31.79M, respectively (Wang X. et al., 2020). Briefly, the study showed enhanced inhibitory activity at early stages compared to the postentry stage (Figure 1). A small-scale study suggested postexposure prophylaxis (PEP) use of UFV in people exposed to COVID-19 patients (Zhang et al., 2020). An additional study determined that arbidol monotherapy was superior to LPV/ RTV against COVID-19 (Zhu et al., 2020). COVID-19 individuals provided with UFV along with LPV/RTV showed far better outcom.